One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile genetic dependencies in cancer cell lines. Here, we describe data from a series of siRNA screens that identify the kinase genetic dependencies in 117 cancer cell lines from ten cancer types. By integrating the siRNA screen data with molecular profiling data, including exome sequencing data, we show how vulnerabilities/genetic dependencies that are associated with mutations in specific cancer driver genes can be identified. By integrating additional data sets into this analysis, including protein-protein interaction data, we also demonstrate that the genetic dependencies associated with many cancer driver genes form dense connections on function...
Synthetic lethality arises when a combination of mutations in multiple genes leads to cell death, wh...
Improved efforts are necessary to define the functional product of cancer mutations currently being ...
The elucidation of the mutational landscape of human cancer has made rapid progress accompanied by t...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
SummaryOne approach to identifying cancer-specific vulnerabilities and therapeutic targets is to pro...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile g...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile g...
Loss-of-function screening using RNA interference or CRISPR approaches can be used to identify genes...
Synthetic lethality arises when a combination of mutations in multiple genes leads to cell death, wh...
Synthetic lethality arises when a combination of mutations in multiple genes leads to cell death, wh...
Improved efforts are necessary to define the functional product of cancer mutations currently being ...
The elucidation of the mutational landscape of human cancer has made rapid progress accompanied by t...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
SummaryOne approach to identifying cancer-specific vulnerabilities and therapeutic targets is to pro...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile g...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile g...
Loss-of-function screening using RNA interference or CRISPR approaches can be used to identify genes...
Synthetic lethality arises when a combination of mutations in multiple genes leads to cell death, wh...
Synthetic lethality arises when a combination of mutations in multiple genes leads to cell death, wh...
Improved efforts are necessary to define the functional product of cancer mutations currently being ...
The elucidation of the mutational landscape of human cancer has made rapid progress accompanied by t...